The US Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk over failures in reporting suspected adverse side effects linked...
Abbott India Ltd has partnered with Novo Nordisk to market a new brand of semaglutide in India, the diabetes drug behind blockbuster weight-loss therapy...
Novo Nordisk shares tumbled in pre-market trading on Monday after its experimental obesity drug CagriSema failed to match the weight-loss efficacy of Eli Lilly’s...